Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ABBV

AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23.

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

My Top 2 Earnings Picks For This Earnings Season

This morning, I woke up to the sound of pounding rain on the roof of my bus and a generator that made me decide to take the day off. Add in some flash flooding, a Wi-Fi signal riding on Starlink, and it's already been a day to remember.

Why Is AbbVie Stock Trading Higher On Thursday?

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.

Here's What to Expect From AbbVie's Next Earnings Report

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

How Is AbbVie's Stock Performance Compared to Other Pharmaceuticals Stocks?

AbbVie has outperformed the Pharmaceuticals industry over the past year, and analysts are moderately optimistic about the stock’s prospects.

inkl

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson Stock: Is JNJ Outperforming the Healthcare Sector?

Johnson & Johnson Stock: Is JNJ Outperforming the Healthcare Sector?

Johnson & Johnson has outpaced the broader healthcare sector over the past year, and analysts remain optimistic about the stock’s prospects.

Options Action: 3 Iron Condor Ideas Amid Market Volatility

Options Action: 3 Iron Condor Ideas Amid Market Volatility

With volatility remaining stubbornly high, option premiums are elevated which could mean it’s a great time for iron condor trades.

Bearish Outlook? Try These 2 Bear Call Spread Trades on Tuesday

Bearish Outlook? Try These 2 Bear Call Spread Trades on Tuesday

If you feel like the market is due for a pause here, then you’re in luck, as there is still a way to profit using options. In this article, we'll show you two bear call spread trades you can make this Tuesday.

Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink?

Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink?

AbbVie has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Earnings Preview: What to Expect From AbbVie's Report

Earnings Preview: What to Expect From AbbVie's Report

AbbVie is scheduled to report its first-quarter results this month, with analysts anticipating a modest growth in earnings.

3 Dividend Kings You’ll Regret Ignoring - Wall Street Sees Big Upside in These Picks

3 Dividend Kings You’ll Regret Ignoring - Wall Street Sees Big Upside in These Picks

These three high-yield Dividend Kings have strong buy ratings and impressive growth potential, and analysts see big upside in these names.

MarketBeat Week in Review – 03/24 - 03/28

Markets got a double dose of bad news about inflation and consumer confidence; next week, the Trump tariffs and Jobs report are likely to keep volatility high

Get all your
news in one place.

100's of premium titles.
One news app.

AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock

AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie has outperformed the healthcare sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

3 Healthcare Stocks Tackling America’s Biggest Medical Challenges

From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare spending and innovative technologies transforming patient care, companies like AbbVie (ABBV), Gilead Sciences (GILD), and Bristol-Myers Squibb (BMY) are tackling some of the biggest challenges and could be poised for long-term growth. Read more….

3 Dividend Growth Stocks for Long-Term Wealth

Dividend-growth stocks offer steady income and long-term value. With the Fed holding rates and inflation expected to ease, now is an opportune time to invest in companies like AbbVie (ABBV), Energy Transfer (ET), and Cheniere Energy (CQP) that consistently raise payouts. Read more….

Get all your
news in one place.

100's of premium titles.
One news app.

These Stocks Missed on Earnings, But Will Rebound Next Quarter

Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year

Is Wall Street Bullish or Bearish on AbbVie Stock?

Despite AbbVie's underperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock's future.

3 High-Conviction Stocks with Strong Buy Ratings from Analysts

It’s easy to get caught up in market noise, but investing in companies backed by strong fundamentals and long-term growth potential can help investors stay the course even during market volatility. Thus, one could consider adding these three high-conviction pharmaceutical stocks, AbbVie (ABBV), Merck & Co. (MRK), and Bristol-Myers Squibb…

AbbVie Investors Trigger Trend-Following Signal: Time to Load Up

AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025.

AbbVie's Quarterly Earnings Preview: What You Need to Know

Pharma giant AbbVie is gearing up to announce its fourth-quarter results later this month and analysts expect a double-digit drop in earnings.

3 Blue-Chip Stocks with Strong Buy Ratings from Analysts

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability and long-term growth potential. Thus, one could consider adding these three fundamentally sound blue-chip stocks, AbbVie (ABBV), Merck & Co. (MRK), and Johnson & Johnson (JNJ), with Strong Buy ratings from…

3 Highest-Yielding Dividend Kings To Buy Today

Start your New Year early by exploring high-yield Dividend Kings with decades of growth, top analyst ratings, and attractive yields for long-term investors.

1 2 3 4 5

People

205,823 stories

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Johnson & Johnson (

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

403,727 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play